Stocktoria
IDEAYA Biosciences, Inc. IDYA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-05-23
IDEAYA Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -72.8% | -4671.1% | -574.9% | -122.7% | -179.9% |
| Net margin | -52.0% | -3921.1% | -483.0% | -115.2% | -178.1% |
| FCF margin | -33.6% | -3592.0% | -502.9% | -177.9% | -209.1% |
| Return on assets | -10.2% | -24.4% | -17.4% | -15.1% | -13.0% |
| Return on equity | -11.1% | -25.9% | -18.2% | -16.8% | -16.5% |
| Current ratio | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 |
| Revenue growth | 3024.4% | -70.1% | -54.1% | 82.3% | 43.0% |
Source: SEC EDGAR filings · CIK 0001676725 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.